Amylyx Pharmaceuticals Inc (AMLX) — Capital Reinvestment Ratio
Latest as of December 2023:
0.03x
Amylyx Pharmaceuticals Inc (AMLX) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($13.55 Million) in capital expenditures ($356.00K). See Amylyx Pharmaceuticals Inc (AMLX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.03x
Capex / Operating Cash Flow
Operating Cash Flow
$13.55 Million
USD
Capital Expenditures
$356.00K
USD
Data as of
Dec 2023
Most recent filing
Amylyx Pharmaceuticals Inc Capital Reinvestment Ratio (2023–2023)
This chart tracks Amylyx Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Amylyx Pharmaceuticals Inc (2023–2023)
Year-by-year Capital Reinvestment Ratio for Amylyx Pharmaceuticals Inc from 2023 to 2023. For live market cap and broader valuation context, see Amylyx Pharmaceuticals Inc stock valuation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.10x | $11.92 Million | $1.24 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow